Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Ixazomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 19/20 | 0.81 |
| ▸ | PSMB8 known ✓ | P28062 | 7/20 | 0.81 |
| ▸ | PSMB9 known ✓ | P28065 | 7/20 | 0.81 |
| ▸ | PSMB6 known ✓ | P28072 | 7/20 | 0.81 |
| ▸ | PSMB10 known ✓ | P40306 | 7/20 | 0.81 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 6/20 | 0.81 |
| ▸ | PSMA7 known ✓ | O14818 | 6/20 | 0.81 |
| ▸ | PSMB1 known ✓ | P20618 | 6/20 | 0.81 |
| ▸ | PSMA1 known ✓ | P25786 | 6/20 | 0.81 |
| ▸ | PSMA2 known ✓ | P25787 | 6/20 | 0.81 |
| ▸ | PSMA3 known ✓ | P25788 | 6/20 | 0.81 |
| ▸ | PSMA4 known ✓ | P25789 | 6/20 | 0.81 |
| ▸ | PSMA5 known ✓ | P28066 | 6/20 | 0.81 |
| ▸ | PSMB4 known ✓ | P28070 | 6/20 | 0.81 |
| ▸ | PSMB3 known ✓ | P49720 | 6/20 | 0.81 |
| ▸ | PSMB2 known ✓ | P49721 | 6/20 | 0.81 |
| ▸ | PSMA6 known ✓ | P60900 | 6/20 | 0.81 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 6/20 | 0.81 |
| ▸ | PSMB7 known ✓ | Q99436 | 6/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ixazomib SCHEMBL29353014 | 0.90 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL18088836 | 0.90 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| Ixazomib SCHEMBL3742758 | 0.90 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL12391076 | 0.84 | PSMB5 (0.84) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL16620476 | 0.82 | PSMB5 (0.73) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL3753435 | 0.82 | PSMB5 (0.85) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL15721497 | 0.81 | PSMB5 (0.80) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253622 | 0.81 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL22604863 | 0.81 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL28826826 | 0.81 | PSMB5 (0.82) | PSMB5PSMB8PSMB9PSMB6PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980078-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD25 ANTIBODY DRUG CONJUGATE AND A FURTHER AGENT | ADC Therapeutics SA (CH) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980079-A1 | COMBINATION THERAPY COMPRISING AN ANTI-CD19 ANTIBODY DRUG CONJUGATE AND A PI3K INHIBITOR OR A SECONDARY AGENT | ADC Therapeutics SA (CH) | 2022-04-13 | — | — | EP | disclosed |